An analysis carried out by Novartis Romania highlights the long delays in Romanian patients' access to innovative medicines, with an average of 460 days from the approval of compensation by the ANMDM. Oncology is the most affected, with 40% of the indications analyzed. Although the assessment process has improved, the compensation steps remain lengthy. The study emphasizes the need for reforms in the reimbursement system to ensure rapid and equitable access to treatment.
Sources
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate/ Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Latest News
20:24
A school in Belfast is rewarding students who attend classes on the day GTA VI launches, when the mathematics exams are also taking place
20:12
A drunk Romanian without a driver's license fled the Austrian police for 62 kilometers, reaching speeds of up to 200 km/h
20:10
Ford warns the EU that excluding the United Kingdom, Turkey, and Morocco could weaken the European automotive industry in the face of China
19:53
A Chinese researcher was dismissed after concealing the death of a young girl during a gene-editing experiment
19:44
Dominic Fritz criticizes the inquiry into the use of cars and SPP personnel at the wedding of Ilie Bolojan’s daughter
See more news